KR20200010505A - 담관암종 치료를 위한 fgfr2 억제제 - Google Patents

담관암종 치료를 위한 fgfr2 억제제 Download PDF

Info

Publication number
KR20200010505A
KR20200010505A KR1020197038249A KR20197038249A KR20200010505A KR 20200010505 A KR20200010505 A KR 20200010505A KR 1020197038249 A KR1020197038249 A KR 1020197038249A KR 20197038249 A KR20197038249 A KR 20197038249A KR 20200010505 A KR20200010505 A KR 20200010505A
Authority
KR
South Korea
Prior art keywords
fgfr
fgfr2
patient
acid
cholangiocarcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038249A
Other languages
English (en)
Korean (ko)
Inventor
재클린 치릴로 버소라리
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20200010505A publication Critical patent/KR20200010505A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020197038249A 2017-06-02 2018-06-01 담관암종 치료를 위한 fgfr2 억제제 Ceased KR20200010505A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17174295.0 2017-06-02
EP17174295 2017-06-02
EP18171315.7 2018-05-08
EP18171315 2018-05-08
PCT/EP2018/064523 WO2018220206A1 (en) 2017-06-02 2018-06-01 Fgfr2 inhibitors for the treatment of cholangiocarcinoma

Publications (1)

Publication Number Publication Date
KR20200010505A true KR20200010505A (ko) 2020-01-30

Family

ID=62555054

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038249A Ceased KR20200010505A (ko) 2017-06-02 2018-06-01 담관암종 치료를 위한 fgfr2 억제제

Country Status (16)

Country Link
US (2) US11707463B2 (enExample)
EP (1) EP3634414A1 (enExample)
JP (2) JP2020521794A (enExample)
KR (1) KR20200010505A (enExample)
CN (1) CN111050769A (enExample)
AU (1) AU2018278271B2 (enExample)
BR (1) BR112019025056A2 (enExample)
CA (1) CA3064317A1 (enExample)
IL (1) IL271058A (enExample)
JO (1) JOP20190280A1 (enExample)
MA (1) MA49248A (enExample)
MX (1) MX2019014366A (enExample)
MY (1) MY204203A (enExample)
PH (1) PH12019502710A1 (enExample)
UA (1) UA126478C2 (enExample)
WO (1) WO2018220206A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370099B (es) 2014-03-26 2019-12-02 Astex Therapeutics Ltd Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
SG11202109902SA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2020284558A1 (en) * 2019-05-28 2022-01-06 Qed Therapeutics, Inc. Methods of treating cholangiocarcinoma
TW202114665A (zh) * 2019-08-05 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途
EP4076449A4 (en) * 2020-01-17 2023-12-06 Beta Pharma, Inc. PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AU2006249847B2 (en) 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
AU2008230880B2 (en) * 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
AU2014207342C1 (en) * 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
CN113957146A (zh) 2014-09-26 2022-01-21 詹森药业有限公司 使用fgfr突变基因组鉴定将对用fgfr抑制剂进行治疗有反应的癌症患者
WO2017070708A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
PH12019502710A1 (en) 2020-06-08
CA3064317A1 (en) 2018-12-06
AU2018278271A1 (en) 2019-12-05
WO2018220206A1 (en) 2018-12-06
JP2023113650A (ja) 2023-08-16
JP2020521794A (ja) 2020-07-27
US12350266B2 (en) 2025-07-08
CN111050769A (zh) 2020-04-21
US20240016801A1 (en) 2024-01-18
JOP20190280A1 (ar) 2019-12-02
IL271058A (en) 2020-01-30
UA126478C2 (uk) 2022-10-12
MX2019014366A (es) 2020-07-27
EP3634414A1 (en) 2020-04-15
BR112019025056A2 (pt) 2020-06-16
MA49248A (fr) 2020-04-15
US11707463B2 (en) 2023-07-25
MY204203A (en) 2024-08-15
AU2018278271B2 (en) 2024-07-04
US20200138809A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
KR20200010505A (ko) 담관암종 치료를 위한 fgfr2 억제제
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
RU2715236C2 (ru) Комбинации
JP7668777B2 (ja) 癌治療
KR20210003780A (ko) Axl 키나제 억제제 및 그의 용도
US11963956B2 (en) Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
IL293206A (en) Combination therapy involving diaryl macrocyclic compounds
JP7761485B2 (ja) 胆管癌の処置
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40051490A (en) Treatment of cholangiocarcinoma
EA043608B1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
HK40029054A (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
EP3946341A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2022082056A1 (en) Dosing regimens for cyclin‑dependent kinase 7 (cdk7) inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210525

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230719

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250220

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250220

X601 Decision of rejection after re-examination